Innovent Biologics Showcases “Dual Innovations” at Oncology R&D Day, Pioneering the Future of Cancer Treatment with Next-Generation IO and ADC Platforms
SAN FRANCISCO and SUZHOU, China, June 30, 2025 /PRNewswire/ -- Innovent Biologics, Inc. ("Innovent") (HKEX: 01801), a world-class biopharmaceutical company that develops, manufactures, and commercializes high-quality medicines for the treatment of oncology, autoimmune, cardiovascular and metabolic, ophthalmology, and other major diseases, held its Oncology R&D Day, unveiling its forward-looking strategy centered on dual innovation in next-generation immuno-oncology (IO) and...
XtalPi and Pfizer Expand Strategic Collaboration to Advance AI-Driven Drug Discovery and Materials Science Simulations
CAMBRIDGE, Mass., June 30, 2025 /PRNewswire/ -- XtalPi (2228.HK), a leading global technology company in integrating artificial intelligence (AI) and robotics to advance the discovery of groundbreaking medicine and innovative materials, announced an expansion of its research collaboration with Pfizer to pioneer a next-generation molecular modeling platform for drug discovery. This...
ESHRE 41st Annual Meeting: Older paternal age linked to higher miscarriage risk and lower live birth rates in donor egg IVF cycles
A new international study presented today at the 41st Annual Meeting of the European Society of Human Reproduction and Embryology (ESHRE) reveals that IVF cycles involving male partners over the age of 45 carry significantly increased miscarriage risks and lower live birth rates – even when young donor eggs are used. PARIS, June...
ESOT Congress 2025: Scientists create functional human islets in 3D printing breakthrough for type 1 diabetes treatment
LONDON, June 29, 2025 /PRNewswire/ -- A team of international scientists has made a major leap forward in diabetes research by successfully 3D printing functional human islets using a novel bioink. Presented today at the ESOT Congress 2025, the new technology could pave the way for more effective and less invasive treatment for people living with type 1...
Mabwell Announces Novel Drug Technology License Agreement with Qilu Pharmaceutical for Albipagrastim alfa for Injection
SHANGHAI, June 27, 2025 /PRNewswire/ -- Mabwell (688062.SH), an innovative biopharmaceutical company with entire industry chain, announced its wholly-owned subsidiary T-mab has entered into an agreement with Qilu Pharmaceutical for Albipagrastim alfa for Injection (R&D code: 8MW0511). Under the terms of the agreement, Mabwell will grant Qilu Pharmaceutical exclusive rights to develop, manufacture, improve, utilize and commercialize the licensed product...
Innovent Announces Mazdutide, First Dual GCG/GLP-1 Receptor Agonist, Received Approval from China’s NMPA for Chronic Weight Management
SAN FRANCISCO and SUZHOU, China, June 27, 2025 /PRNewswire/ -- Innovent Biologics, Inc. ("Innovent") (HKEX: 01801), a world-class biopharmaceutical company that develops, manufactures and commercializes high-quality medicines for the treatment of oncologic, autoimmune, cardiovascular and metabolic, ophthalmologic and other major diseases, announces that China's National Medical Products Administration (NMPA) has approved mazdutide, a first-in-class dual glucagon (GCG)/glucagon-like peptide-1 (GLP-1) receptor agonist,...
Drug-Free Nasal Spray LUCA V-Defense Creates a Protective Shield Against Viruses and Allergies
SEOUL, South Korea, June 27, 2025 /PRNewswire/ -- As respiratory illnesses like COVID-19, influenza, and Mycoplasma pneumonia continue to spread, the need for safe, non-pharmaceutical prevention options is growing. South Korea–based biotech firm LUCA AICELL has developed LUCA V-Defense Nasal Spray, a drug-free nasal spray designed to form a protective barrier on the nasal lining—offering a modern solution in the...
Avio Health Launches World’s First Functional Medicine LLM for Emagene Life, Transforming Personalized Healthcare
KUALA LUMPUR, Malaysia, June 27, 2025 /PRNewswire/ -- Avio Health, a deep-tech company dedicated to advancing healthcare through data analytics and machine learning, today announced the launch of the world's first Functional Medicine-based Large Language Model (LLM) developed exclusively for Emagene.Life. This breakthrough follows 18 months of intensive research and development, delivering a new standard in personalized healthcare. Through sophisticated machine learning, Avio Health's system rapidly analyzes and unifies patient blood biomarker data from around the globe. Clinicians can now go from manually interpreting labs...
TransThera Publishes Translational Studies of Tinengotinib (TT-00420) against Cholangiocarcinoma on Annals of Oncology
NANJING, China and GAITHERSBURG, Md., June 27, 2025 /PRNewswire/ -- TransThera Sciences Inc. ("TransThera") announced that the translational studies of tinengotinib in CCA with acquired resistance to FGFR inhibitors were published in Annals of Oncology (IF 56.7). Dr. Peng Peng, Vice President at TransThera, serves as the co-first author. CCA is an aggressive bile duct cancer often driven by...
Yidu Tech’s AI Agents Now Handle 20% of Hospital Tasks: Human-Machine Collaboration Model Showcased at Summer Davos
TIANJIN, China, June 27, 2025 /PRNewswire/ -- From June 24 to 26, the World Economic Forum 2025 Annual Meeting of the New Champions (the 16th Summer Davos Forum) was held in Tianjin. Artificial intelligence, as the new frontier of global economic growth, was one of the hottest topics of this year's forum. Dialogue on the Theme of "AI+ Era"...
